MetaCap

Zai Lab Limited ADR (ZLAB)

NASDAQ: ZLABHealth CareBiotechnology: Pharmaceutical PreparationsUSD

21.03-0.89 (-4.06%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

ZLAB stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$1.80
52-week range
15.96 – 29.02
Day range
20.02 – 21.15
Volume / Avg
1.44M / 991.34K
Beta
—

52-week range

$15.96$29.02

ZLAB stock today

Zai Lab (ZLAB) closed at $21.03 on Nov 20, down 4.06% (-$0.89), versus the S&P 500's 3.70% decline. Shares are 27.5% below their 52-week high of $29.02, set on Nov 9, 2026 and 31.8% above the 52-week low of $15.96, in the middle of the past year's range. ZLAB is up 19.2% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 5.0%.

Zai Lab has posted a net loss over the last twelve months (EPS of -$1.80), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Zai Lab

Company profile

Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. The company has a strategic collaboration with Tesaro, Inc., NovoCure Ltd., Deciphera Pharmaceuticals, LLC, Paratek Bermuda Ltd., argent BV, Turning Point Therapeutics, Inc., Entasis Therapeutics Holdings Inc., Karuna Therapeutics, Inc., Pfizer Inc., Amgen Inc., and with Boehringer Ingelheim GmbH.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Ying Du Ph.D.
Headquarters
Pudong
Employees
1,784
IPO year
2017

Financial highlights

Full financials

In fiscal 2025, Zai Lab generated $460.2 million in revenue, up 15.3% from fiscal 2024, its 7th consecutive year of revenue growth. Zai Lab reported a net loss of $175.5 million, compared with a loss of $257.1 million a year earlier. Gross margin was 58.6% (down from 63.1%) and operating margin -49.9%.

Zai Lab annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$460.16M$398.99M$266.72M$215.04M$144.31M
Growth+15.33%+49.59%+24.03%+49.01%+194.77%
Net income$-175.54M$-257.10M$-334.62M$-443.29M$-704.47M
EPS (diluted)$-0.16$-0.26$-0.35$-0.46$-0.76

Analyst forecast

Forecast

Consensus (12 analysts)

strong_buy

Avg. price target

$34.21+62.67%

  • Strong buy 2
  • Buy 9
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $24.25High $56.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 5, 2026
EPS actual vs est.
$-0.04 vs —

ZLAB news

All ZLAB news

Zai Lab peers

Health Care sector
ZLAB peer companies
CompanyPrice% ChgMarket capCompare
XNCRXencor Inc.33.26-2.21%$2.50Bvs ZLAB
IDYAIDEAYA Biosciences Inc.25.56-2.33%$2.47Bvs ZLAB
SLSSELLAS Life Sciences Group Inc.13.66-8.08%$2.78Bvs ZLAB
MBXMBX Biosciences Inc.49.55-7.23%$2.46Bvs ZLAB
TLXTelix Pharmaceuticals Limited ADR8.37-3.90%$2.84Bvs ZLAB
PBHPrestige Consumer Healthcare Inc.49.63+0.06%$2.35Bvs ZLAB
DYNDyne Therapeutics Inc.15.50-3.31%$2.90Bvs ZLAB
HCMHUTCHMED (China) Limited ADR13.22-1.71%$2.30Bvs ZLAB

Indexes, lists and sector

Zai Lab stock FAQ

What is Zai Lab's stock price today?

ZLAB last traded at $21.03 as of Nov 20, 4:00 PM EST, down 4.06% on the day. Prices are delayed at least 15 minutes.

Who is Zai Lab's CEO?

Dr. Ying Du Ph.D. is the chief executive officer of Zai Lab Limited ADR, which has about 1,784 employees.

What is the ZLAB 52-week high?

The 52-week high for ZLAB is $29.02 and the 52-week low is $15.96. The stock is currently 27.5% below its high.

Compare ZLAB